Dafna Capital Management LLC Spero Therapeutics, Inc. Transaction History

Dafna Capital Management LLC

$389 Million
Q3 2024

A detailed history of Dafna Capital Management LLC transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Dafna Capital Management LLC holds 125,000 shares of SPRO stock, worth $128,750. This represents 0.04% of its overall portfolio holdings.

Number of Shares

125,000

Previous 125,000 -0.0%

Holding current value

$128,750

Previous $162,000 3.09%

% of portfolio

0.04%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.68 - $2.2 $85,000 - $275,000	125,000 New	125,000 $250,000
Q4 2020 Feb 16, 2021	SELL	$11.65 - $22.07 $1.17 Million - $2.21 Million	-100,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.96 - $14.12 $896,000 - $1.41 Million	100,000 New	100,000 $1.12 Million
Q2 2020 Aug 14, 2020	SELL	$7.27 - $14.18 $349,708 - $682,100	-48,103 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.27 - $10.41 $253,502 - $500,752	48,103 New	48,103 $389,000
Q4 2019 Feb 14, 2020	SELL	$9.46 - $12.16 $372,676 - $479,043	-39,395 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$9.01 - $12.55 $275,751 - $384,092	-30,605 Reduced 43.72%	39,395 $418,000
Q3 2018 Nov 14, 2018	BUY	$9.69 - $17.79 $678,300 - $1.25 Million	70,000 New	70,000 $736,000
Q2 2018 Aug 13, 2018	SELL	$10.41 - $17.85 $307,553 - $527,360	-29,544 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$9.96 - $14.61 $244,458 - $358,587	24,544 Added 490.88%	29,544 $421,000
Q4 2017 Feb 14, 2018	BUY	$10.43 - $14.75 $52,150 - $73,750	5,000	5,000 $59,000

Others Institutions Holding SPRO

# of Institutions

Shares Held

13.9M

Call Options Held

200

Put Options Held

200

View Full List

About Spero Therapeutics, Inc.

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $36.1M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

More about SPRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Spero Therapeutics, Inc. Transaction History